Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study
Viganò, M., Dengler, T., Mattei, M.F., Poncelet, A., Vanhaecke, J., Vermes, E., Kleinloog, R., Li, Y., Gezahegen, Y., Delgado, J.F.
Published in Transplant infectious disease (01.02.2010)
Published in Transplant infectious disease (01.02.2010)
Get full text
Journal Article
16: Concentration-Controlled Everolimus Versus MMF in De Novo Heart Transplant Patients: Incidence of CMV Infection at 12 Months Post-Transplant in a Randomized Trial
Dengler, T, Viganò, M, Magelli, C, Guillemain, R, Varnous, S, Gerosa, G, Poncelet, A, Vanhaecke, J, Li, Y, Gezahegen, Y
Published in The Journal of heart and lung transplantation (2008)
Published in The Journal of heart and lung transplantation (2008)
Get full text
Journal Article
397: Everolimus with reduced cyclosporine exposure vs. MMF and conventional cyclosporine: Results from a study in de novo heart transplant recipients
Lehmkuhl, H, Livi, U, Boissonnat, P, Arizon, J, Vigano, M, Magelli, C, Almenar, L, Abeywickrama, K.H, Gezahegen, Y
Published in The Journal of heart and lung transplantation (2007)
Published in The Journal of heart and lung transplantation (2007)
Get full text
Journal Article